<SEC-DOCUMENT>0001104659-24-071070.txt : 20240613
<SEC-HEADER>0001104659-24-071070.hdr.sgml : 20240613
<ACCEPTANCE-DATETIME>20240613080525
ACCESSION NUMBER:		0001104659-24-071070
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240613
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240613
DATE AS OF CHANGE:		20240613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37372
		FILM NUMBER:		241040049

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2417144d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:coll="http://collegiumpharma.com/20240613">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_coll_collegiumpharma.com_20240613 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20240613_20240613 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001267565 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000004" name="dei:EntityCentralIndexKey">0001267565</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="coll-20240613.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-06-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_904_edei--DocumentType_c20240613__20240613_z1X4kVubYAQa"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <b><span id="xdx_905_edei--DocumentPeriodEndDate_c20240613__20240613_zDSaKi4FcPV5"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 13, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20240613__20240613_zcwpgrbO5b5g"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000011" name="dei:EntityRegistrantName">COLLEGIUM PHARMACEUTICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240613__20240613_zsiUkOM7iXF2"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityFileNumber_c20240613__20240613_zJyT65HMyMe3"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000013" name="dei:EntityFileNumber">001-37372</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20240613__20240613_zrxUQsOI1Tn4"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000014" name="dei:EntityTaxIdentificationNumber">03-0416362</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other
    Jurisdiction<br/>
 of Incorporation or Organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification<br/>
 No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: center; width: 100%"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20240613__20240613_zBW7UMcF3YNf"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000015" name="dei:EntityAddressAddressLine1">100 Technology Center Drive</ix:nonNumeric></span></b></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine2_c20240613__20240613_zTWRisEFiIBc"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></b></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20240613__20240613_zXPiDMQwDXi9"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000017" name="dei:EntityAddressCityOrTown">Stoughton</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20240613__20240613_z5oqQlOHv4Oc"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b> <b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20240613__20240613_z1RyriH5Ahoa"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000019" name="dei:EntityAddressPostalZipCode">02072</ix:nonNumeric></span></b></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: center">(Address of principal executive offices) (Zip Code)</td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90A_edei--CityAreaCode_c20240613__20240613_zR8dQDCX3YI1"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000020" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20240613__20240613_zFuGReBOuJk"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000021" name="dei:LocalPhoneNumber">713-3699</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of
    each class</b></span></td>
    <td style="vertical-align: bottom; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each
    exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--Security12bTitle_c20240613__20240613_zbF4ElspTno6"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000022" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--TradingSymbol_c20240613__20240613_z23NhZhzUCT5"><ix:nonNumeric contextRef="AsOf2024-06-13" id="Fact000023" name="dei:TradingSymbol">COLL</ix:nonNumeric></span></span></td>
    <td style="padding: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SecurityExchangeName_c20240613__20240613_zypRCCx2sqIi"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt-sec:exchnameen" id="Fact000024" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20240613__20240613_zyo0SJN3Kqd4"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:booleanfalse" id="Fact000025" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span>&#160;
Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span id="xdx_907_edei--SolicitingMaterial_c20240613__20240613_zgolhPQxac53"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:booleanfalse" id="Fact000026" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;
Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20240613__20240613_zZWk3ipSkijk"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160; Pre-commencement communications
pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20240613__20240613_zdCkAAjKJBkg"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:booleanfalse" id="Fact000028" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;
Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20240613__20240613_zPpZrgQaXBki" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-06-13" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span></p>








<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><b>Item 8.01</b></td>
    <td style="font-size: 10pt; text-align: justify"><b>&#160;Other Information.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June&#160;13, 2024, Collegium Pharmaceutical,&#160;Inc. issued a
press release announcing the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has granted pediatric exclusivity for Nucynta&#174;
and Nucynta&#174; ER (&#8220;the Nucynta Franchise&#8221;), extending exclusivity of the Nucynta Franchise an additional six months, to
January&#160;3, 2027, for Nucynta and December&#160;27, 2025, for Nucynta ER. A copy of the press release is attached as Exhibit&#160;99.1
to this Current Report on Form&#160;8-K and is incorporated by reference into this Item 8.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><b>Item 9.01</b></td>
    <td style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><a href="tm2417144d1_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td style="text-align: justify"><a href="tm2417144d1_ex99-1.htm" style="-sec-extract: exhibit">Press Release, dated June&#160;13, 2024</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td style="text-align: justify">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: June&#160;13, 2024</span></td>
    <td colspan="2"><span style="font-size: 10pt">Collegium Pharmaceutical,&#160;Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 47%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Colleen Tupper</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Name: Colleen Tupper</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Title: Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi42huujSUkWsIqWI22CnEmwzZRL/juQtjS3iMDAM733vCTERa1qZFhlOy7KACru+1R6hxAYZ7RmDI9tsUwi3xItxnrX1w/sDMwoMBmY+VUoHYbDejcM6BZnEahGrBKRKZQKHnYi+eka2MTVab3QL2tZwYOrZoNf8GhMq/SRL3WuoOiI7QzaF2VSO8huUnCnY010/iK8OiiIT0WSYSKyZbn1w5U+P9ktC3mIX6txI/zf6AAUaSoo= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2417144d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Collegium Obtains Six Month Extension of U.S.
Pediatric Exclusivity for Nucynta Franchise</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>STOUGHTON, Mass., June&nbsp;13, 2024
</B></FONT>-- Collegium Pharmaceutical,&nbsp;Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to
improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA)
has granted pediatric exclusivity for Nucynta<SUP>&reg;</SUP> and Nucynta<SUP>&reg;</SUP> ER (&ldquo;the Nucynta Franchise&rdquo;). In
2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June&nbsp;27,
2025, to July&nbsp;3, 2026. FDA&rsquo;s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional
six months, to January&nbsp;3, 2027, for Nucynta and December&nbsp;27, 2025, for Nucynta ER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased with FDA&rsquo;s grant of pediatric exclusivity
for the Nucynta Franchise,&rdquo; said Thomas Smith, M.D., Collegium&rsquo;s Chief Medical Officer. &ldquo;This grant of pediatric exclusivity
enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of
people living with serious medical conditions and the communities we serve.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nucynta is currently approved in the U.S. for the management of acute
pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative
treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nucynta ER is currently approved in the U.S. for the management of
severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks
associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic
pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic
and for which alternative treatment options are inadequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Please see Important Safety Information
that follows below and complete product information, including the Boxed Warning, available at </FONT>www.NUCYNTA.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Collegium Pharmaceutical,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Collegium is a leading, diversified specialty
pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium&rsquo;s headquarters
are located in&nbsp;Stoughton, Massachusetts. For more information, please visit the Company&rsquo;s website at&nbsp;</FONT>www.collegiumpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NUCYNTA<SUP>&reg;</SUP> (tapentadol) INDICATIONS AND USAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NUCYNTA<SUP>&reg;</SUP> (tapentadol) tablets are:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A strong prescription pain medicine that contains an opioid (narcotic) that
is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other
pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An opioid pain medicine that can put you at risk for overdose and death.
Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING: SERIOUS AND LIFE-THREATENING RISKS
    FROM USE OF NUCYNTA TABLETS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Addiction, Abuse, and Misuse</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because the use of NUCYNTA tablets exposes patients and other users
    to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient&rsquo;s risk prior to prescribing
    and reassess regularly for the development of these behaviors and conditions.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Life-Threatening Respiratory Depression</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Serious, life-threatening, or fatal respiratory depression may occur
    with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory
    depression, proper dosing and titration of NUCYNTA tablets are essential.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Accidental Ingestion</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accidental ingestion of even one dose of NUCYNTA tablets, especially
    by children, can result in a fatal overdose of tapentadol.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Concomitant use of opioids with benzodiazepines or other central
    nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve
    concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment
    options are inadequate.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Neonatal Opioid Withdrawal Syndrome</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If opioid use is required for an extended period of time in a pregnant
    woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated.
    Ensure that management by neonatology experts will be available at delivery.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Healthcare providers are strongly encouraged to complete a REMS-compliant
    education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide
    with each prescription.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important information about NUCYNTA tablets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Get emergency help or call 911 right away if you take too much NUCYNTA
(overdose) tablets.</B> When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious
or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for
the emergency treatment of an opioid overdose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol,
or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems,
coma, and death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Never give anyone else your NUCYNTA tablets. They could die from taking it.
Selling or giving away NUCYNTA tablets is against the law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Store NUCYNTA tablets securely, out of sight and reach of children, and in
a location not accessible by others, including visitors to the home.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Do not take NUCYNTA tablets if you have:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">severe asthma, trouble breathing, or other lung problems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a bowel blockage or have narrowing of the stomach or intestines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Before taking NUCYNTA tablets, tell your healthcare provider if
you have a history of:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">head injury, seizures</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">problems urinating</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">abuse of street or prescription drugs, alcohol addiction, opioid overdose
or mental health problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">liver, kidney, thyroid problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">pancreas or gallbladder problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tell your healthcare provider if you:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>notice your pain getting worse.</B> If your pain gets worse after you
take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider
if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>are pregnant or planning to become pregnant.</B> Use of NUCYNTA tablets
for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not
recognized and treated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>are breastfeeding.</B> NUCYNTA tablets pass into breast milk and may harm
your baby.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are living in a household where there are small children or someone who has
abused street or prescription drugs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are taking prescription or over-the-counter medicines, vitamins, or herbal
supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>When taking NUCYNTA tablets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your
healthcare provider.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Use the lowest dose possible for the shortest time needed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">For acute (short-term) pain, you may only need to take NUCYNTA tablets for
a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for
directions on how to safely throw away (dispose of) your unused NUCYNTA tablets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take your prescribed dose every 4-6 hours, at the same time every day. Do
not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Call your healthcare provider if the dose you are taking does not control
your pain.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA
tablets without talking to your healthcare provider.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing
down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal
of unused medicines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>While taking NUCYNTA tablets, DO NOT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Drive or operate heavy machinery, until you know how NUCYNTA tablets affect
you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Drink alcohol or use prescription or over-the-counter medicines that contain
alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The possible side effects of NUCYNTA tablets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness,
abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Get emergency medical help or call 911 right away if you have:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling
of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature,
trouble walking, stiff muscles, or mental changes such as confusion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">These are not all of the possible side
effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For more information, go to </FONT>dailymed.nlm.nih.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>See full Prescribing Information,
including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at
</B></FONT><B>Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NUCYNTA<SUP>&reg;</SUP> ER (tapentadol) INDICATIONS AND USAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NUCYNTA<SUP>&reg;</SUP> ER (tapentadol) extended-release tablets
are:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A strong prescription pain medicine that contains an opioid (narcotic) that
is used to manage severe and persistent pain in adults that requires an extended treatment period with a daily opioid pain medicine, when
other pain medicines do not treat your pain well enough or you cannot tolerate them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Also used in adults to manage severe and persistent pain from damaged nerves
(neuropathic pain) that happens with diabetes, and that requires an extended treatment period with a daily opioid pain medicine, when
other pain medicines do not treat your pain well enough or you cannot tolerate them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A long-acting (extended-release) opioid pain medicine that can put you at
risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse
that can lead to death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Not to be taken on an &ldquo;as needed&rdquo; basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA ER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING: SERIOUS AND LIFE-THREATENING RISKS
    FROM USE OF NUCYNTA ER</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Addiction, Abuse, and Misuse</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because the use of NUCYNTA ER exposes patients and other users to
    the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient&rsquo;s risk prior to prescribing
    and reassess all patients regularly for the development of these behaviors and conditions.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Life-Threatening Respiratory Depression</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Serious, life-threatening, or fatal respiratory depression may occur
    with use of NUCYNTA ER, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper
    dosing and titration of NUCYNTA ER are essential. Instruct patients to swallow NUCYNTA ER tablets whole; crushing, chewing, or dissolving
    NUCYNTA ER tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Accidental Ingestion</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accidental ingestion of even one dose of NUCYNTA ER, especially
    by children, can result in a fatal overdose of tapentadol. Interaction With Alcohol Instruct patients not to consume alcoholic beverages
    or use prescription or non-prescription products that contain alcohol while taking NUCYNTA ER. The co-ingestion of alcohol with NUCYNTA
    ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Concomitant use of opioids with benzodiazepines or other central
    nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve
    concomitant prescribing of NUCYNTA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment
    options are inadequate.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Neonatal Opioid Withdrawal Syndrome (NOWS)</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If opioid use is required for an extended period of time in a pregnant
    woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by
    neonatology experts will be available at delivery.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Healthcare providers are strongly encouraged to complete a REMS-compliant
    education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide
    with each prescription.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important information about NUCYNTA ER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Get emergency help or call 911 right away if you take too much NUCYNTA
ER (overdose). </B>When you first start taking NUCYNTA ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening
breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment
of an opioid overdose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Taking NUCYNTA ER with other opioid medicines, benzodiazepines, alcohol,
or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems,
coma, and death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Never give anyone else your NUCYNTA ER. They could die from taking it. Selling
or giving away NUCYNTA ER is against the law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Store NUCYNTA ER securely, out of sight and reach of children, and in a location
not accessible by others, including visitors to the home.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Do not take NUCYNTA ER if you have:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">severe asthma, trouble breathing, or other lung problems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a bowel blockage or have narrowing of the stomach or intestines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Before taking NUCYNTA ER, tell your healthcare provider if you have
a history of:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">head injury, seizures</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">problems urinating</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">abuse of street or prescription drugs, alcohol addiction, opioid overdose
or mental health problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">liver, kidney, thyroid problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">pancreas or gallbladder problems</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tell your healthcare provider if you:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">notice your pain getting worse. If your pain gets worse after you take NUCYNTA
ER, do not take more of NUCYNTA ER without first talking to your healthcare provider. Talk to your healthcare provider if the pain that
you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA ER.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>are pregnant or planning to become pregnant.</B> Use of NUCYNTA ER for
an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized
and treated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>are breastfeeding.</B> Not recommended during treatment with NUCYNTA ER.
It may harm your baby.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are living in a household where there are small children or someone who has
abused street or prescription drugs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are taking prescription or over-the-counter medicines, vitamins, or herbal
supplements. Taking NUCYNTA ER with certain other medicines can cause serious side effects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>When taking NUCYNTA ER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Do not change your dose. Take NUCYNTA ER exactly as prescribed by your healthcare
provider. Use the lowest effective dose for the shortest time needed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take your prescribed dose every 12 hours, at the same time every day. Do
not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Swallow NUCYNTA ER whole. Do not cut, break, chew, crush, dissolve, snort,
or inject NUCYNTA ER because this may cause you to overdose and die.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Call your healthcare provider if the dose you are taking does not control
your pain.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Do not stop taking NUCYNTA ER without talking to your healthcare provider.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dispose of expired, unwanted, or unused NUCYNTA ER by promptly flushing down
the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal
of unused medicines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>While taking NUCYNTA ER, DO NOT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Drive or operate heavy machinery until you know how NUCYNTA ER affects you.
NUCYNTA ER can make you sleepy, dizzy, or lightheaded.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Drink alcohol or use prescription or over-the-counter medicines containing
alcohol. Using products containing alcohol during treatment with NUCYNTA ER may cause you to overdose and die.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The possible side effects of NUCYNTA ER are:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness,
abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Get emergency medical help or call 911 right away if you have:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling
of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature,
trouble walking, stiff muscles, or mental changes such as confusion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">agitation, hallucinations, coma, feeling overheated, or heavy sweating.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">These are not all the possible side effects
of NUCYNTA ER. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For more information go to </FONT>dailymed.nlm.nih.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>See full Prescribing Information,
including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, accompanying this piece or at </B></FONT><B>Nucynta.com/ERpi.
Speak to your healthcare provider if you have questions about Nucynta ER.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2417144d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as &quot;predicts,&quot; &quot;forecasts,&quot;
 &quot;believes,&quot; &quot;potential,&quot; &quot;proposed,&quot; &quot;continue,&quot; &quot;estimates,&quot; &quot;anticipates,&quot;
 &quot;expects,&quot; &quot;plans,&quot; &quot;intends,&quot; &quot;may,&quot; &quot;could,&quot; &quot;might,&quot; &quot;should&quot;
or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking
statements contained in this press release include, among others, statements related to current and future market opportunities for our
products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not
historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results,
performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others:
unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial
performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with
licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products,
and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and
our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and
degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing
market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the
outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient
for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations
and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient
intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the
manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the
accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are
described under the heading &quot;Risk Factors&quot; in our Annual Reports on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q and
other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise,
after the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investor Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B></B></FONT>Christopher James, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President,&nbsp;Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@collegiumpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B></B></FONT>Marissa Samuels</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">communications@collegiumpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>coll-20240613.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaWHObOdzZR+mYkxtmBwbQmanysufj9EhC/pSqKGAWIM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:coll="http://collegiumpharma.com/20240613" elementFormDefault="qualified" targetNamespace="http://collegiumpharma.com/20240613">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://collegiumpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="coll-20240613_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="coll-20240613_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>coll-20240613_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>coll-20240613_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://collegiumpharma.com/role/Cover" xlink:href="coll-20240613.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://collegiumpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2417144d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2417144d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- /8# 2(  A$! Q$!_\0
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M+N'4K_3Y;1#=>,O%,]Q+XLNO%&M:_P##C0/$?ACPEX:U+PC'^V.H_P#!&?\
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MK0A-3E3J3C'D]HN=2E'E3CS\EXW_ ':_:X_:7\ ?LA_L\?$G]H_XJV?B>[\
M_#/3-&U3Q-:>$M,LM8\22VNN^(=#\*QII^G:E<V>EW,L6H>(+*YEB&HVZ-%;
MW#K*S1.I]H\!>,=.^(?@CP;X\T-+E-$\=>%M \7:/]HBDBO(M(\3:#;:WIQN
M(F&4O$AN85EBY,;MM(#$&ORM_P""]F6_X))?MD(H);_A$/ "A0,L2?B_\/>
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M#$9D\5"695L.Z3K*MSQ6&O.C*O!\C=_=;7Z/_P#!>7_E$_\ MB?]BO\ #_\
M]7+\.*X7]LG]N&Z_X)^?\$AOAS\??#6CVGB3X@W/PA_9]^'GPRL-9>,Z5+XU
M\4>#M#CL=<UD[7ADM?#&@6&L^,OL8VG6[S0+/080;G5X=W=?\%Y 3_P2?_;#
MP,Y\+_#\#'.3_P +E^' P/7GBOF?_@IK^R!\3OVT?^"+OPM^'GP<T5_$?Q2\
M#_#O]F_XP>$?"MI>I:ZIXEF\)_#V.P\5:%82$2)?:GJ7@O7M=A\/65O%)-?Z
M[#96]LDT[P(/FN&H9=4RW@6CG$(_V:^/\1/&S;C[2C0CDF'C*?LZDH4W!RE"
M$W6E3I-S5.4TJC3]3.*N+I8W-ZV$G+_DD)05-)N%>M_;&9RC3YDG%U(PDY*"
MDZBC44N3EDI/XM_9L_X)(_\ !+#QY\)M(^*?[=O[0W@_]HK]JSXPZ=IWC_XO
M>-O$O[5>F>'O^$9^(?C!7UJ\TSPW8>!/&WA:SO7T)KNV\.Z?=^*X/$%H\^EO
M:6T4>ELOAE/:_P#@EIJ.F?L4?M_?%[_@E]\/?CW%^T/^RYXT^!T'[4W[.GBQ
MO&&D>+M9^$]QI_BBW\"ZY\+)-5\.ZUJWABXCN\MK,FGZ5IWA.VMK?3=%U"+P
M48_&>LW%OS_[%_@;_@WV_:1^ G@;QKXB^&G['/PV^*MAX/TVR^,'P\^*NMZ%
M\.?'O@GQGHFAP67CNQ\0Z'XJ\6:5J,FAZ?JYN);#68[>336MDBO%N8YI'C@^
MQO\ @G*W_!)?QG^T3\9;C_@GE^SUX7M/$GP/T$>%M>_:2\!> M1TKX4:Y>>+
MM1NAK_@+P;X\FU"YL]:UN*[TFPO_ !/>Z;H3V%U;317EC>7L,@E;WLTQE664
M\48.=3CG.LB="M2PE+/.%\GP&0Y'B9YA4E0S7!YMAXQJX>M##4ZU.BL-64\0
MJ\O:PFG[1>?A(*7^KF+2R_*<PH0RITZF78BA6Q.-K1I5W++<QI49U*F'PU>,
MFYSQ,*,5)2C.2LHOX#\3? [Q-_P7"_X*/?M.^&?C3X^\6^#_ -@3]@#XB:?\
M$8/@]X(\2ZCX4U+XS?%KP]<^(=-UR_\ $^IZ-<IY=I%XKT?6FCU\DZ[H?A.Z
M\(:1X%M= \5:MXR\867T+^T+_P $&O@S\&/!VK?&S_@F)K'CO]DW]IOX=>&]
M=U+0X]-^)7Q)\?>"OBU EDUQJ_PV^(6@_$+Q5XEN[G2_&=O&=%EUVSUZ33=)
MN'B^W^$O$S![=?%_@E^T)H7_  2+_P""G?[;OP>_:WL;_P"''[./[=?QHU?]
MI3X!_'ZZTJ[O_A?%XD\13:MJ_B[1?$/B 0MJMF\T_B6#P]XA#K<+X+U;PIIN
MKWT5C\-M=LO$B?HS^UI_P6,_9$^'GPQ\1:)^S=\7?#7[5_[0_B[PYXBL/A#\
M*?V:M1T7XXZ]<>+[70[X:;K'B*Z\(WNM^&?"?A+P[>6<NH^*M9\275MINEV%
MM=W%^T<4<]3CL3Q='/N#H9+A,9#AE99PQ+(<&L%A?]7\;E]*G:O6Q68X:-2C
M4Q4\=_:%3'TLXQ='$8.G5IRC2HJ<'5A4<EEE'$N,Q>)5;-IXC/W76+FJ-:E7
MK2H<N!P2Q$Z-2MA:"ITXX>5&-6E4YYRISE>=H_\ @W\P_P#P2$_8Z(B8*NB?
M%J-$EA<.57X__%:RQ=*EY>PW&(DWL3>3811*P"A,?&7_  :VD-^PG\>B%9A;
M_MO_ !21&8WDBKCX8?!1RUL+R]O;N.W\ZXNY8[%G!!N3M5?.9F^UO^#?O _X
M(_\ [':OE2-)^,;8/!VM^T!\5B&P<9!W CC!!![C/Q;_ ,&M0(_83^/VX%?^
M,X_BB>01Q'\+_@3O//&%RH?TR,XS7A9FG5R/Q1<^6.(EQGPM.IA*,U/#T6LS
MSN4HX5PYZ=6BN1WJ49UJ;C&$G**Y7+NPE:3S'PWJ).--Y3F*DVI1C!K+</&T
MGHHM\R34G!W?+9N7*>U_\&]^\_L__MJRR.<_\/+?VH=XD=I99%32?A6NGFXG
M:[OHA<QQ(D0739#IH+,L40=069_P5+"C_@I/_P $,XE+*@_:,_:!>(0E"S26
M_@GX?FPC^SRWME!]CB:XB$DL,=X4;RBJ(7#2>&?\$9_VB?@I^RO\0?\ @H?^
MQ3^T-\3O!?P8^-/A_P#;W^-GQ5T;0/B?KVF> QXQ\">/M.\)P^%O$7AO4?%U
MUI5EKDNH:;X-G\406^F-.UQH&HV.L6\<VG2I<+Y7^VC^VQ\%_P!IS_@L?_P2
M7^'WP&\:Z1\3?"/P%^,?Q$D\??$OP'<1>(/AT/'WQ-T+3M.7P/8>*M,:\T'7
MO$_A72?!TFH:W/HNI7-OH]KXMMKB^6$VCL/:GEN-J^(O$.94,&Z^72P7%.(A
MCYPJ+ UJ-3@Q0I/#XR5..#Q#J3G&$*='%59RJ6IJ#J?NUY]+,<-3X2RC"3J4
MGC(YQE+EA>>FL324.+'*<JN'=3ZQ2BH?O'*I0IQ<%[1OD7.=G_P<BZ+\0]0\
M6?\ !+:?X/:U+X9^-$W[7\NB?"C7Y8WNH]&\;:_+X"T_0KR2!KRT@%D-:TS0
MIC9QQ7378EN'CM\B3SG_ +57_!O)^Q'\//V*?C/XO^'NG?$B;]JGX8?#/QO\
M6-"_:-U?XH^/;CQ;XL^)/A7P^WC:YO/$_APZT/!1LO%?B+09+6:TL?#[:GIF
MF796T\21ED1O8?\ @NNZ/^T-_P $66W (O\ P4@^%6]BP(56\:_#>-2QSA0T
MKQ(I) ,DJ(/G=0?VF_:Y"G]E+]I@'Y9'_9_^,#F,G#CR_AWXAW':?FP-ZYXX
MW+D\@UY3S?&8+)?#/"X:,,+0GB\5/,:=*47&K[+BFNZ,L1"+;2HTJ]9Q]I[.
M*A7=2W*XR.RO@:&,Q/'M6O&-2NN6.7SNI*$:G#^!57V;3:?M*E*G'W6^:5.<
M5>49PC_,K_P2^_X)M?#7_@J]^SKX7_;O_P""D>H^,_C]\0?B%93?"[X<Z$GC
M?QK\//"?A7X>_!2*P^#JZ_)%\.?%'A?7M1^(7BW7_ OBCQ)KWB%]>CT2ZU76
MIKA_"RW.1)Z=_P $L/AGX@_X)Y_\%;/VQ_\ @FSX4U_Q!XC_ &;?$7P.L_VG
M?@OI7B/4YM3U7P4UYXE\(PWFGP75YJ5YY%R]MXTU'PAXBU10MKXND^'?@C5+
MP:=>->I+]X?\&[*C_AS_ /LFMC+BZ^/[(G.Z3ROVFOC!%(4'5A%(#')@'8ZE
M6(8$5X1INHVNE?\ !RM\1-3U2:"RTS3_ /@EK'<:C=SR)"D4!^*'@=FFN))&
M58X@+6[Q)(RH?LT^6_<R%?1K9GB\QS3Q&RITZ6*RV>19W'+<,Y4W2I3I9AED
MJ:PL%HIRY$TJ'-*JG4BHSC'W5_9^'PV&X$Q%&DOKD,UR!XZJHMMPC@<RCS5)
M6:BJ;J2C.4Y05/G@IRIN:Y_Z+PZ@*NY!Q\N6 W!54$CKG!(R1QEO<45\:? C
M]L_X.?M#>+]?\$> ;CQ%:>*-/@\1:I%I7BFQBT#^W+'P5J'A?2/&=]I=QI!U
M.X74/!]QX^^'-CXOT+7HM+U?0KGQAH%A<V$5[!J4-N5^/X^CCL#B9X:651O3
MC2_B4^67O4H22LX[*_+'5Z175-+]"PU>G5I*;J03<ZJLYTUM6JKK-/5)-::I
MIJZ:;^UZ^&OV[OV#O@;_ ,%!/@7K'P.^..B"2!P^J^"/'NEP1Q^,?AIXRM%E
M_L/Q?X2U)F:2'4-+=U:^TZX)TS7(2]K=PO&P,/W+52:)74*5DQ_LKN([= /3
MOGH:[</C\5EF*PV-PN)JX*K0JQJ1Q5!S5:E--<G(Z:<TI.ZDTFDE[RLSGQ>"
MPN8X:K@L;3]KA:R2JP?5*[3TUTN[6U[.^_\ /5_P2=_X)#>#O^"1-A\5OCK\
M6_C7%XW^)GC30)/!^L:]I[77AWX;^$OAUI^NV>LV]I%X>N95.L>*?$NHZ?8Z
M[J5U<Q7,VB7\M]X9^'ZRIK.J7'BWW[XR_L>_L+?\%.+9/'"ZSJGA#XQZ?9_V
M7>>(O"E[I6@>.OL>F;UM[/Q9X-UAO$&DZOH3SLDD%];VT>JR6X2WL/%ELB-Y
M7Z9_&OX,>'_CA\.]1^'WB:6\MK:]6VNK/4K..2*ZTC5;!A):ZM81(Y!F@=SY
M=G=/+&X+KM8@R'^;WXS_  6\<?L]>.I?"WB%BSQPOJ_A#Q%IT7V*'5="B)6;
M6=/O+*Z2*&_B8$2:7>2NP()VXY/\^^./TFO'+P0XRRGQ,R'))YODF&C4PN-S
M_#9UF^49E4E66#AAZ=7&X2GB\IH-<M14:6>Y9BX8AN:PL8R6)3^4SCA;AW&9
M,\AQ^597F'#JC-5,%F&#EB*SE.]U@YNA-T)-1O.:E3YFZ>O[M):%Q_P;A27.
MJ;D_;"3^Q]O"O\#$_MC<!P/MC_%#[/MR!\WD^AV]*_07X _L!_L0?\$Z(!\0
M_%>M+XI^)=AISR:9\0/BA=Z7J.N65RN ;3X;>$$D9](U&7<,7>CVVH:[,@>.
MX\320-(A_-&/XU?&*"![(_%7XF_9(UW26!\>^, L:G^)[O\ M<!5]V8#GMVS
M?"/A#Q]\9O&^F>&- AU3Q1XMUJ<VCF_=+BZ 52S:G>WEU<R6.BVJJ"3=3B&$
M#DO7YYQG^U6\9/$+)EP3E&2Y[+/<]G1IX')\7FG#N>4<^Q<I1;PDJ'!V4Y3F
MN,J4G4C.%'-9Y;@*N*>%P^.JTL)7Q-:G^>\/>%/A9PGCEG&0^'=/#8ZCB*+P
M5;%8BGB4Y2G+GEA:4JU>6&C3?)S*=*FI<T+-\GN_JS^UU^Q_\#?^"HOP5TGQ
MMX&\0Z5X=^+'A_2V?X=_$6""VNM1T 7FVZ?P+X]TFV;[0^E:C<&1IK.[,FH>
M"O$#OK_A=KVPFU*T\2>T?L!_\$__ (>?L)_#JXT70YQXL^*/B\6,_P 2_B3/
M9I#J&O7-@CK9:+IB2J[Z5X.\-^9)#X>TQ)&FE3;<:A+/.3CVO]F;]FSP]^SM
MX%ET6RN[S6?%&OM:ZCXO\1NLT$6H:DL84VNG6$ZK_9FAP-O$-B%%P TC2L6,
M03ZH *D (><Y."?PR0<'T_'UX_L'@KQ'\5\;X2Y#PCQCF<\#A:O_  JYGPYA
M:E2.#R_'XWV=7$8%8>=3%5\-*A4Y*F+R]8[&Y?A<QE7IY>WA:%.4_P!!AX?<
M'4N,EQ__ *MX+#\2RPJPU+%TU"52/M(<M5MPCRJI&*C!5':7)>*FUH1,I56D
M0 R8P1C)!Z' Z?KCGITJ?^'\0?P((_F*@3=\^$D4CH2I&?7' SQGMGL!ZV3)
M'@#<GS#*C*\YZ8&1GGTKFE"%/FI1J2:M1Y5.7NTW>5E&<FHWG=+E4F[JUKM(
M^R2E&2YH0@TYSE[-J7.I\KN^5-ODLN9VZ]+V/F_]HK]E;]G_ /:O^'5U\+/V
MBOA/X3^+7@2XO?[431?%&G>;)I>JQQAH=>\/:I9O#KOAG7XG\X0ZQX6O=&U6
M-[B81L%GFW_E5:?\&W/_  29M/$46O'X ^*KR""Z-S'H5Q\:?C!)HRPX_P"/
M83MX\'B,H#W_ +=Y/&W%?N^)X#D!XR1D$"0<$ D@C)Q@ DY[ GI09XHU#>8A
M!P=VX;2I.T$'(!!8[=W3/ ZU[V!X@XCRVF\-@<SQ>"HR7[ZC1KU4JJDI)24(
MMJ#MS7DHQ<F[IN4;GE5\IR7,:\:]7!X;%59R:A*?).THR2:C[WO-NR:CS--)
M-7LCS3X7?"GX??!7P'X;^&?PD\%Z)X \!>$+"'2O#OA3PUIRZ?HNBV=J<206
MD&U);B2?,F;Z<2R7!/GO*TLCM+\N_M8?\$W_ -B[]MVXT?4OVG?V?O"/Q*US
M0[.?2M,\4+J'BKP9XSM-'$IFMM+C\<_#G6_!_BZ715G:64^&[OQ ^G-)<22D
MF1'>7[I^T6\F]1<1AXBN\>8F4+C<F\!B4WKEER!O W#N:59X%3<LJ $.V&=.
M1&0KGK@A&*ASCY&90<$BN##X_'X?'5,QP>:8NEF%1M^WA5K1G&2;<FZT)1J*
M4KMRDZJE*SO>VG77PF$=#ZGB,NPTL%12]I2G&'+::3IMPDHI*2BW&Z2:^!R2
M;/B;]EO_ ()X_L:?L8PZG/\ LU?L\^!?A?JNN:>^FZOXEMX]:\1>-KW2YW26
M\TBY\=>+]9\5^,CHK7"Q7$7AR'Q"NFB>WCE1A(%:/U+]H?\ 9:^ O[6?@_0/
M /[0_P ,="^*?@WPWXTT;X@:/H'B6*_2WL_%ND66HZ=IFO1M9SVDJW%CIFO:
MW9F"1MI2Z>)Q'N0CZ)+HR;RV54\[2"%. 3DCA>#GISBH(KFRG*B*[MYF*>8!
M%/'(Q3&X/A'/R%2&##(VD-G!!-U,PQ];&?VIB\RQ>(QD(N$\1*I7JMRK>[%^
MVDZLW.W-&/[QNTI122%A\)@806'H87#X>A&$JE&A2Y(R]G&RJU/9QDI*E3<J
M:G-QY(N45.<7**EY5\8O@G\-?VA/ACXO^#_QF\(Z=X_^&OCFVMK/Q/X.UJ.[
MBTK6X--U'3M4M8+@P20W4$4>J:7:WD1BG!8HLJNZY)[KP_X=TKPIX>T+PKX?
MTY=.T#PWI6E^']&TVT4A+/1],LHM,TZU1I#N\NRMHH\88LJQ*23SNWFNK10"
MUU;D-'YBXFC^>/89/,7+8,?EJTF\978I;.T%A()4(X?:20N"0,DXV\$YR<C
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MKM)5':Z=*-FKN_\ /%K/Q\^.]I^R/XU^"L7CSXK'XDW/P?UO]J+PU\9?[?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139889013256480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COLLEGIUM PHARMACEUTICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0416362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stoughton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">713-3699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COLL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<F]P<R]A<' N>&UL4$L! A0#%     @ K$#-6/F7VD/O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ K$#-
M6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "L0,U8YTZB+FT$   P$0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ K$#-
M6)^@&_"Q @  X@P   T              ( !L0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "L0,U8EXJ[',     3 @  "P              @ &-#P
M7W)E;',O+G)E;'-02P$"% ,4    " "L0,U8JL0B%C,!   B @  #P
M        @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ K$#-6"0>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ K$#-6&60>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2417144d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://collegiumpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>coll-20240613.xsd</File>
    <File>coll-20240613_lab.xml</File>
    <File>coll-20240613_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2417144d1_8k.htm">tm2417144d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2417144d1_8k.htm": {
   "nsprefix": "coll",
   "nsuri": "http://collegiumpharma.com/20240613",
   "dts": {
    "schema": {
     "local": [
      "coll-20240613.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "coll-20240613_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "coll-20240613_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2417144d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://collegiumpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2417144d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2417144d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-24-071070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-071070-xbrl.zip
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ML9T[II($A(?-5T<&&8&TU@L+BPVF]/,V31A)X8G(4+EEP6JQR4)#$A +-E\
M"[D4::T7%BXW1*SE]/:3X*_98YF?%6P;H';+1J?E)B-6:4"L=/D#F-$AJ(C1
M*77]P+,[)!0OLBS"+;5('6,#FC68:>E" @8RUZ*%DDA=;[GA&5IR]#4E*'LD
MZ++\&;IZ)OBB'E^_-!)%ZH6(8E7.8BQL"'6)G?_J"&BX]=LC+640(/7:@W^'
MI(I .L0Q-;>285$_C\M-S#.R =]VZ ]Q1=!0\YJC/GT0- TT:3*5AS5/KO-
MI")]9C.J)[>'EW@-D>.5L<6@L3"N*8)@!+0%+8OKOQ7@)W?>=D63Z(IR#%]E
M:6@<9\QKVS.2Y1T$ 1'0=@6ER,N%*%=ZZ?_/F#V)[7,6[>\$CPA13UFEU6C5
M=_UM8+1;9M[4I"9-@T(#XNPM?@$"#U6@6AT?:C.6SXMYZJ%QE<V-1T^+1RP/
MX.TV2]4,*HW!5\$[@QS?7AC0 .,F0T=$0.@-L G=<,@C41[Z 17!J!;MZ?PL
M/60!)/'G_3UY($*]=[ DN^RSW-%3QQG&@%C79V^#FV.>S/4&!@'A6]U"IWHI
MJE> 5NH9L;(*]+NJ!.6UV'Z_O+[I6GZ2F_4F^=<*IT1N^2]02P,$%     @
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M+G16SGEJRL+G0OAQD#VI@*IG;21GTDD ?*>=X5]+J9;+9AU#HPH(11\TP9&
M-UD1- >&-KR^F6 EM]U.WH;*$JI$+O.TF:9X*C+O#J)T^Z_0#RF+$Y(<4)'0
M>:&9@F3321?R;Z8C>4]'KBW"#9<?J1=GV7@$L5K]_JH*PN/=<X::G6?Z=;L2
MPH:Z$JJ[KN9M&YU!@":A!/ L^)?8*OU1$WSM[CYMI$9NA[^%(FVI;<5H;6O8
MMD.LM3JG5I\KE:\7GT^?MSL+M:'.';ZB<TL<[A+7UBC@*@>6(8GLGK*% GH=
M?DT%7)O]-G252P02WBE21"8,W9_1>$CX)OUBA@KY+F@8B)-3&*"!98S9, :"
M-7G6BFVDDCZDGN*,6"!I2.?\C'8A8W /D&;0'@<L'(G$P0<&6B!RDQ\QXV<
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MEO>#RXO]%[&: &+Q3QK\IGN]OMA^X;F?TW /(5HAN!<QW=OIB..@V0#L (X
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M7^3JZ7@,T..+S<8Z\Z<6M=4FD$M[UL4+9PKT,,HTCD*;FI$=LJ6R.'B;#(4
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M"65%)(K[H:R2T*KLBV!=*("&= DDA!TU $[>D4%5 PNC1 /9%"E_(F""*>,
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M\]*^/#@_^@-#B"\_#D]/]O\?4$L! A0#%     @ K$#-6(?W\RLN P  ^ L
M !$              ( !     &-O;&PM,C R-# V,3,N>'-D4$L! A0#%
M  @ K$#-6)8CKTW]"@  @(8  !4              ( !70,  &-O;&PM,C R
M-# V,3-?;&%B+GAM;%!+ 0(4 Q0    ( *Q S5@+L'396P<  .-7   5
M          "  8T.  !C;VQL+3(P,C0P-C$S7W!R92YX;6Q02P$"% ,4
M" "L0,U8^6'=[>41  #@6   $@              @ $;%@  =&TR-#$W,30T
M9#%?.&LN:'1M4$L! A0#%     @ K$#-6'($E?$K'@  @00! !8
M     ( !,"@  '1M,C0Q-S$T-&0Q7V5X.3DM,2YH=&U02P4&      4 !0!)
) 0  CT8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2417144d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="coll-20240613.xsd" xlink:type="simple"/>
    <context id="AsOf2024-06-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267565</identifier>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-06-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-06-13" id="Fact000004">0001267565</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-06-13" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-06-13" id="Fact000010">2024-06-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-06-13" id="Fact000011">COLLEGIUM PHARMACEUTICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-06-13" id="Fact000012">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-06-13" id="Fact000013">001-37372</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-06-13" id="Fact000014">03-0416362</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-06-13" id="Fact000015">100 Technology Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-06-13" id="Fact000016">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-06-13" id="Fact000017">Stoughton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-06-13" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-06-13" id="Fact000019">02072</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-06-13" id="Fact000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-06-13" id="Fact000021">713-3699</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="AsOf2024-06-13" id="Fact000022">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-06-13" id="Fact000023">COLL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-06-13" id="Fact000024">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="AsOf2024-06-13" id="Fact000025">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-06-13" id="Fact000026">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-06-13" id="Fact000027">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-06-13" id="Fact000028">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-06-13" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
